31.23
2.43%
+0.74
After Hours:
31.23
Perrigo Company plc stock is currently priced at $31.23, with a 24-hour trading volume of 943.27K.
It has seen a +2.43% increased in the last 24 hours and a -0.29% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $30.39 pivot point. If it approaches the $31.43 resistance level, significant changes may occur.
Previous Close:
$30.49
Open:
$30.48
24h Volume:
943.27K
Market Cap:
$4.23B
Revenue:
$4.66B
Net Income/Loss:
$-12.70M
P/E Ratio:
-62.46
EPS:
-0.5
Net Cash Flow:
$303.80M
1W Performance:
+3.96%
1M Performance:
-0.29%
6M Performance:
+6.66%
1Y Performance:
-13.47%
Perrigo Company plc Stock (PRGO) Company Profile
Name
Perrigo Company plc
Sector
Phone
353 1 709 4000
Address
Treasury Building, Lower Grand Canal Street, Dublin
Perrigo Company plc Stock (PRGO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-17-23 | Initiated | Piper Sandler | Overweight |
Mar-07-23 | Initiated | Canaccord Genuity | Buy |
Sep-14-22 | Upgrade | Argus | Hold → Buy |
Sep-06-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Sep-30-21 | Upgrade | Jefferies | Hold → Buy |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Jan-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Apr-17-20 | Downgrade | Argus | Buy → Hold |
Mar-24-20 | Upgrade | JP Morgan | Neutral → Overweight |
Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Oct-11-19 | Upgrade | Argus | Hold → Buy |
Mar-20-19 | Initiated | SunTrust | Hold |
Nov-13-18 | Downgrade | Berenberg | Buy → Hold |
Aug-10-18 | Reiterated | Stifel | Hold |
Jul-30-18 | Downgrade | Argus | Buy → Hold |
Jul-12-18 | Downgrade | Goldman | Neutral → Sell |
Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
Dec-08-17 | Upgrade | Argus | Hold → Buy |
Nov-10-17 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
Oct-05-17 | Reiterated | UBS | Buy |
Sep-07-17 | Initiated | Oppenheimer | Outperform |
Aug-11-17 | Upgrade | Goldman | Sell → Neutral |
Aug-11-17 | Reiterated | RBC Capital Mkts | Underperform |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
Jun-05-17 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
Mar-03-17 | Reiterated | B. Riley & Co. | Neutral |
View All
Perrigo Company plc Stock (PRGO) Latest News
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Zacks Investment Research
Around $2M Bet On Tile Shop Holdings? Check Out These 4 Stocks Insiders Are Buying
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
Zacks Investment Research
Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics
Zacks Investment Research
Perrigo Company plc Stock (PRGO) Financials Data
Perrigo Company plc (PRGO) Revenue 2024
PRGO reported a revenue (TTM) of $4.66 billion for the quarter ending December 31, 2023, a +4.58% rise year-over-year.
Perrigo Company plc (PRGO) Net Income 2024
PRGO net income (TTM) was -$12.70 million for the quarter ending December 31, 2023, a +90.97% increase year-over-year.
Perrigo Company plc (PRGO) Cash Flow 2024
PRGO recorded a free cash flow (TTM) of $303.80 million for the quarter ending December 31, 2023, a +44.05% increase year-over-year.
Perrigo Company plc (PRGO) Earnings per Share 2024
PRGO earnings per share (TTM) was -$0.10 for the quarter ending December 31, 2023, a +90.38% growth year-over-year.
About Perrigo Company plc
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc has a collaborative agreement with the Sol-Gel Technologies Ltd. for the development, manufacturing, and commercialization of an ivermectin cream in the United States. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Cap:
|
Volume (24h):